Stem cell therapy for heart failure

The science and current progress

M. Ian Phillips, Yao Liang Tang, Kai Pinkernell

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Cell therapy, particularly with stem cells, has created great interest as a solution to the fact that there are limited treatments for postischemic heart disease and none that can regenerate damaged heart cells to strengthen cardiac performance. From the first efforts with myoblasts to recent clinical trials with bone marrow-derived stem cells, early reports of cell therapy suggest improvement in cardiac performance as well as other clinical end points. Based on these exciting but tentative results, other stem cell types are being explored for their particular advantages as a source of adult stem cells. Autologous adipose-derived stem cells are multilinear and can be obtained relatively easily in large quantities from patients; cardiac-derived stem cells are highly appropriate for engraftment in their natural niche, the heart. Human umbilical cord blood cells are potentially forever young and allogenic adult mesenchymal stem cells appear not to evoke the graft versus host reaction. Human embryonic stem cells are effective and can be scaled up for supply purposes. The recent discovery of induced pluripotentcy in human adult stem cells, with only three transcription factor genes, opens a whole new approach to making autologous human pluripotent stem cells from skin or other available tissues. Despite the excitement, stem cells may have to be genetically modified with heme oxygenase, Akt or other genes to survive transplantation in a hypoxic environment. Homing factors and hormones secreted from transplanted stem cells may be more important than cells if they provide the necessary stimulus to trigger cardiac regrowth to replace scar tissue. As we await results from larger and more prolonged clinical trials, the science of stem cell therapy in cardiac disease keeps progressing.

Original languageEnglish (US)
Pages (from-to)285-298
Number of pages14
JournalFuture Cardiology
Volume4
Issue number3
DOIs
StatePublished - May 1 2008
Externally publishedYes

Fingerprint

Cell- and Tissue-Based Therapy
Stem Cells
Heart Failure
Adult Stem Cells
Heart Diseases
Clinical Trials
Heme Oxygenase (Decyclizing)
Pluripotent Stem Cells
Myoblasts
Mesenchymal Stromal Cells
Fetal Blood
Genes
Cicatrix
Young Adult
Blood Cells
Transcription Factors
Transplantation
Bone Marrow
Hormones
Transplants

Keywords

  • Adipose derived
  • Akt
  • Cardiac derived
  • Cell therapy
  • Genetic modification
  • Heme oxygenase
  • Human embryonic stem cells
  • Induced pluripotency
  • Ischemic heart disease
  • Myoblasts
  • Stem cells
  • Umbilical cord blood cells

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Molecular Medicine

Cite this

Stem cell therapy for heart failure : The science and current progress. / Phillips, M. Ian; Tang, Yao Liang; Pinkernell, Kai.

In: Future Cardiology, Vol. 4, No. 3, 01.05.2008, p. 285-298.

Research output: Contribution to journalReview article

Phillips, M. Ian ; Tang, Yao Liang ; Pinkernell, Kai. / Stem cell therapy for heart failure : The science and current progress. In: Future Cardiology. 2008 ; Vol. 4, No. 3. pp. 285-298.
@article{cb78c1c087e5457e983f946f3b80e2f8,
title = "Stem cell therapy for heart failure: The science and current progress",
abstract = "Cell therapy, particularly with stem cells, has created great interest as a solution to the fact that there are limited treatments for postischemic heart disease and none that can regenerate damaged heart cells to strengthen cardiac performance. From the first efforts with myoblasts to recent clinical trials with bone marrow-derived stem cells, early reports of cell therapy suggest improvement in cardiac performance as well as other clinical end points. Based on these exciting but tentative results, other stem cell types are being explored for their particular advantages as a source of adult stem cells. Autologous adipose-derived stem cells are multilinear and can be obtained relatively easily in large quantities from patients; cardiac-derived stem cells are highly appropriate for engraftment in their natural niche, the heart. Human umbilical cord blood cells are potentially forever young and allogenic adult mesenchymal stem cells appear not to evoke the graft versus host reaction. Human embryonic stem cells are effective and can be scaled up for supply purposes. The recent discovery of induced pluripotentcy in human adult stem cells, with only three transcription factor genes, opens a whole new approach to making autologous human pluripotent stem cells from skin or other available tissues. Despite the excitement, stem cells may have to be genetically modified with heme oxygenase, Akt or other genes to survive transplantation in a hypoxic environment. Homing factors and hormones secreted from transplanted stem cells may be more important than cells if they provide the necessary stimulus to trigger cardiac regrowth to replace scar tissue. As we await results from larger and more prolonged clinical trials, the science of stem cell therapy in cardiac disease keeps progressing.",
keywords = "Adipose derived, Akt, Cardiac derived, Cell therapy, Genetic modification, Heme oxygenase, Human embryonic stem cells, Induced pluripotency, Ischemic heart disease, Myoblasts, Stem cells, Umbilical cord blood cells",
author = "Phillips, {M. Ian} and Tang, {Yao Liang} and Kai Pinkernell",
year = "2008",
month = "5",
day = "1",
doi = "10.2217/14796678.4.3.285",
language = "English (US)",
volume = "4",
pages = "285--298",
journal = "Future Cardiology",
issn = "1479-6678",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Stem cell therapy for heart failure

T2 - The science and current progress

AU - Phillips, M. Ian

AU - Tang, Yao Liang

AU - Pinkernell, Kai

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Cell therapy, particularly with stem cells, has created great interest as a solution to the fact that there are limited treatments for postischemic heart disease and none that can regenerate damaged heart cells to strengthen cardiac performance. From the first efforts with myoblasts to recent clinical trials with bone marrow-derived stem cells, early reports of cell therapy suggest improvement in cardiac performance as well as other clinical end points. Based on these exciting but tentative results, other stem cell types are being explored for their particular advantages as a source of adult stem cells. Autologous adipose-derived stem cells are multilinear and can be obtained relatively easily in large quantities from patients; cardiac-derived stem cells are highly appropriate for engraftment in their natural niche, the heart. Human umbilical cord blood cells are potentially forever young and allogenic adult mesenchymal stem cells appear not to evoke the graft versus host reaction. Human embryonic stem cells are effective and can be scaled up for supply purposes. The recent discovery of induced pluripotentcy in human adult stem cells, with only three transcription factor genes, opens a whole new approach to making autologous human pluripotent stem cells from skin or other available tissues. Despite the excitement, stem cells may have to be genetically modified with heme oxygenase, Akt or other genes to survive transplantation in a hypoxic environment. Homing factors and hormones secreted from transplanted stem cells may be more important than cells if they provide the necessary stimulus to trigger cardiac regrowth to replace scar tissue. As we await results from larger and more prolonged clinical trials, the science of stem cell therapy in cardiac disease keeps progressing.

AB - Cell therapy, particularly with stem cells, has created great interest as a solution to the fact that there are limited treatments for postischemic heart disease and none that can regenerate damaged heart cells to strengthen cardiac performance. From the first efforts with myoblasts to recent clinical trials with bone marrow-derived stem cells, early reports of cell therapy suggest improvement in cardiac performance as well as other clinical end points. Based on these exciting but tentative results, other stem cell types are being explored for their particular advantages as a source of adult stem cells. Autologous adipose-derived stem cells are multilinear and can be obtained relatively easily in large quantities from patients; cardiac-derived stem cells are highly appropriate for engraftment in their natural niche, the heart. Human umbilical cord blood cells are potentially forever young and allogenic adult mesenchymal stem cells appear not to evoke the graft versus host reaction. Human embryonic stem cells are effective and can be scaled up for supply purposes. The recent discovery of induced pluripotentcy in human adult stem cells, with only three transcription factor genes, opens a whole new approach to making autologous human pluripotent stem cells from skin or other available tissues. Despite the excitement, stem cells may have to be genetically modified with heme oxygenase, Akt or other genes to survive transplantation in a hypoxic environment. Homing factors and hormones secreted from transplanted stem cells may be more important than cells if they provide the necessary stimulus to trigger cardiac regrowth to replace scar tissue. As we await results from larger and more prolonged clinical trials, the science of stem cell therapy in cardiac disease keeps progressing.

KW - Adipose derived

KW - Akt

KW - Cardiac derived

KW - Cell therapy

KW - Genetic modification

KW - Heme oxygenase

KW - Human embryonic stem cells

KW - Induced pluripotency

KW - Ischemic heart disease

KW - Myoblasts

KW - Stem cells

KW - Umbilical cord blood cells

UR - http://www.scopus.com/inward/record.url?scp=47249139504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249139504&partnerID=8YFLogxK

U2 - 10.2217/14796678.4.3.285

DO - 10.2217/14796678.4.3.285

M3 - Review article

VL - 4

SP - 285

EP - 298

JO - Future Cardiology

JF - Future Cardiology

SN - 1479-6678

IS - 3

ER -